Abstract
Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders and it is characterized by episodes of abdominal pain and altered bowel functions. The specific bowel disturbances of diarrhea, constipation or an alternation between the two defines the IBS subtypes of diarrhea-predominant, constipation-predominant, and mixed or alternating IBS. Because of the abnormalities in bowel states associated with each IBS subtype, it is not likely that one agent would successfully treat all three subtypes. As a result, clinical trials have focused, for the most part, on one IBS subtype. Over the past 2 decades very few agents have achieved regulatory approval for the treatment of IBS. In the present article we review publications reporting on phase 2 and phase 3 studies evaluating agents to potentially be used in the treatment of patients with IBS.
Keywords: Irritable bowel syndrome, diarrhea-predominant, constipation-predominant, abdominal pain, bowel functions, gastrointestinal disorders, diarrhea, chronic, placebo, Alosetron
Reviews on Recent Clinical Trials
Title:Clinical Trials in Irritable Bowel Syndrome: A Review
Volume: 8 Issue: 1
Author(s): Claire M. Ervin and Allen W. Mangel
Affiliation:
Keywords: Irritable bowel syndrome, diarrhea-predominant, constipation-predominant, abdominal pain, bowel functions, gastrointestinal disorders, diarrhea, chronic, placebo, Alosetron
Abstract: Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders and it is characterized by episodes of abdominal pain and altered bowel functions. The specific bowel disturbances of diarrhea, constipation or an alternation between the two defines the IBS subtypes of diarrhea-predominant, constipation-predominant, and mixed or alternating IBS. Because of the abnormalities in bowel states associated with each IBS subtype, it is not likely that one agent would successfully treat all three subtypes. As a result, clinical trials have focused, for the most part, on one IBS subtype. Over the past 2 decades very few agents have achieved regulatory approval for the treatment of IBS. In the present article we review publications reporting on phase 2 and phase 3 studies evaluating agents to potentially be used in the treatment of patients with IBS.
Export Options
About this article
Cite this article as:
M. Ervin Claire and W. Mangel Allen, Clinical Trials in Irritable Bowel Syndrome: A Review, Reviews on Recent Clinical Trials 2013; 8 (1) . https://dx.doi.org/10.2174/1574887111308010003
DOI https://dx.doi.org/10.2174/1574887111308010003 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids
Current Pharmaceutical Design Dysregulation of Neurotrophic and Haematopoietic Growth Factors in Alzheimer’s Disease: From Pathophysiology to Novel Treatment Strategies
Current Alzheimer Research Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016)
Recent Patents on Anti-Cancer Drug Discovery Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands
Current Medicinal Chemistry Erythropoietin: New Approaches to Improved Molecular Designs and Therapeutic Alternatives
Current Pharmaceutical Design Immunosuppressive Properties of Mesenchymal Stem Cells: Advances and Applications
Current Molecular Medicine Human Milk has Anti-Oxidant Properties to Protect Premature Infants
Current Pediatric Reviews Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry Selectins as Targets in Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Non Pregnant Human Uterus as Source of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Nitric Oxide and Dietary Factors: Part II Cholesterol, Fat, Amino Acids,Proteins and Carbohydrate
Vascular Disease Prevention (Discontinued) Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets Connection between JAK/STAT and PPARγ Signaling During the Progression of Multiple Sclerosis: Insights into the Modulation of T-Cells and Immune Responses in the Brain
Current Molecular Pharmacology Modulation of Cardiovascular Function by Adipokines
Cardiovascular & Hematological Disorders-Drug Targets Drug-Induced Hypokalaemia
Current Drug Safety Editorial [Hot Topic:Structuring Chemical Information for Quicker and More Reliable Drug Safety Assessment (Guest Editor: Romualdo Benigni)]
Current Computer-Aided Drug Design Crocetin Attenuates Spatial Learning Dysfunction and Hippocampal Injury in a Model of Vascular Dementia
Current Neurovascular Research Curcumin: Structure-Activity Relationship Towards its Role as a Versatile Multi-Targeted Therapeutics
Mini-Reviews in Organic Chemistry